PENG+LFCN Block vs QIPB for Total Hip Arthroplasty

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorAntalya City Hospital

About this trial

This randomized clinical trial aims to evaluate and compare the analgesic efficacy and functional outcomes of the quadro-iliac plane block (QIPB) and the pericapsular nerve group (PENG) block combined with lateral femoral cutaneous nerve(LFCN) block in patients undergoing total hip arthroplasty. The primary outcome is the Numeric Rating Scale (NRS) within the first 48 hours after surgery. Secondary outcomes include postoperative total opioid consumption, ıncidence of quadriceps motor block, time to first ambulation, block performance time, falls, length of hospital stay, block- related complications(hematoma,local anesthetic systemic complications, vascular puncture, and infection), patient satisfaction assessed using a Likert scale, and incidence of postoperative nausea and vomiting.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age between 18 and 80 years

American Society of Anesthesiologists physical status I-III

Scheduled for elective unilateral primary total hip arthroplasty

Surgery planned under spinal anesthesia

Disqualifiers

Refusal to participate

Revision total hip arthroplasty

Bilateral total hip arthroplasty

Contraindication to spinal anesthesia

Trial design

Design model

Parallel

Treatments tested in this trial

  • Quadro iliac Plane Block(QİPB)

    Procedure/Surgery

    Participants allocated to the QIPB group will receive an ultrasound-guided quadro-iliac plane block after spinal anesthesia. Following standard aseptic preparation, 30 mL of 0.25% bupivacaine will be administered into the target fascial plane under ultrasound guidance after confirming the absence of blood on aspiration.

  • PENG Block and LFCN Blok

    Procedure/Surgery

    Participants in the PENG group will undergo an ultrasound-guided pericapsular nerve group (PENG) block after spinal anesthesia. A total of 20 mL of 0.25% bupivacaine will be administered.

  • Lateral femoral cutaneous nerve block(LFCN)

    Procedure/Surgery

    Participants in the LFCN group will undergo an ultrasound-guided lateral femoral cutaneous nerve block after spinal anesthesia. A total of 10 mL of 0.25% bupivacaine will be administered.

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: quadro-iliac plane block (QIPB)Active comparator 1 intervention
Group B: pericapsular nerve group (PENG) block combined with lateral femoral cutaneous nerve blockActive comparator 2 interventions

Trial outcomes

Primary outcomes

1

Postoperative pain scores

Postoperative pain intensity will be assessed using an 11-point Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst imaginable pain. Pain scores at rest will be recorded in the post-anesthesia care unit and at postoperative 6, 24, 36, and 48 hours. Pain scores during movement will be assessed during passive flexion of the operated hip at postoperative 6, 24, 36, and 48 hours.

Time frame
Postoperative 6, 24, 36, and 48 hours

Secondary outcomes

1

Postoperative opioid consumption

Total postoperative opioid consumption will be recorded and cumulative opioid consumption will be calculated at postoperative 24 and 48 hours.

Time frame
Postoperative 24 and 48 hours
2

Incidence of quadriceps motor block

Quadriceps motor block will be assessed using knee extension testing and graded as: 0 = normal strength 1. = paresis 2. = paralysis. Motor block incidence will be defined as the presence of paresis or paralysis.

Time frame
Postoperative 3, 6, and 24 hours
3

Time to first ambulation

Time from the end of surgery to the first successful ambulation.

Time frame
Postoperative day 1
4

Patient satisfaction

Patient satisfaction with postoperative analgesia will be assessed using a Likert scale.

Time frame
Postoperative 48 hours

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: